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Abstract A matrix metalloproteinase (MMP)-like gene was
identified in mouse to contain a conserved MMP catalytic
domain and an RRRR motif. It lacks a classic cysteine switch,
but it possesses two novel motifs: a cysteine array (Cys-X6-Cys-
X8-Cys-X10-Cys-X3-Cys-X2-Cys), and a novel Ig-fold. It is
named CA-MMP after the distinct cysteine array motif, and
little is known about its biochemical function. In an attempt to
characterize CA-MMP activity, the full-length sequence was
expressed in mammalian cells and its product found to be cell-
associated without detectable secretion. In light of this unusual
finding, a chimera combining the catalytic domain of CA-MMP
with the prodomain of stromelysin-3 was constructed to express a
fully active enzyme in mammalian cells. Purified CA-MMP
catalytic domain expresses proteolytic activity against protein
substrates in an MMP inhibitor sensitive fashion. Taken
together, it is concluded that CA-MMP is an MMP with
distinct structure, biochemical properties and evolutionary
history that may define a new subclass of the MMP superfamily.
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1. Introduction
The extracellular matrix (ECM), made of various collagens,
elastins, proteoglycans, and glycoproteins, undergoes exten-
sive remodeling or breakdown under many physiological as
well as pathological conditions [1,2]. The primary enzymes
responsible for ECM breakdown appear to belong to a family
of metal-dependent, neutral pH optimal endopeptidases called
matrix metalloproteinases (MMPs) [2^4]. Synthesized as latent
zymogens, MMPs undergo obligatory activation before they
can express any proteolytic activity against ECM component
[5]. Once activated, MMPs can be inhibited by proteinase
inhibitors both general such as K2M and speci¢c such as
TIMPs [6,7]. Throughout evolution, various mechanisms
such as zymogen latency and shields of proteinase inhibitor
have been evolved gradually to ¢ne tune MMP activities in
normal tissues.
Functional repertoire of domains or motifs which confer
substrate speci¢city and regulatory mechanism for MMPs dis-
covered so far include: (1) a signal peptide for secretion, (2) a
cysteine switch motif PRCGXPD for latency, (3) an RXKR
motif for furin mediated zymogen activation, (4) a catalytic
domain built around an HEXXHXXXXXH motif, (5) a ¢-
bronectin-like domain for binding to substrates, (6) a hemo-
pexin-like domain for both substrate and inhibitor interac-
tions, (7) a transmembrane domain for cellular localization
[4,6]. It seems that the ancestral MMP has a domain structure
resembling that of matrilysin containing the signal peptide,
PRCGXPD and the catalytic domain [8]. Based on this de-
sign, additional acquisition of various domains and motifs led
to the current family of about 20 MMPs. For example, gela-
tinase A is made of all the above domains except RXKR and
transmembrane domains, whereas its activators, the MT-
MMPs, possess all except the ¢bronectin-like motif [9^11].
This modular design re£ects both the general principle of
gene evolution as well as speci¢c need of matrix degrading
enzymes. While all these motifs are integral parts of MMPs,
only two are unique for this gene family: the catalytic and the
PRCGXPD domains.
The symbiotic relationship between the catalytic and
PRCGXPD domains is illustrated elegantly by the cysteine
switch model proposed by Van Wart and Birkedal-Hanson
[12]. The Cys residue in the PRCGXPD motif is proposed
to bind to a catalytic zinc coordinated by the
HEXXHXXGXXH motif in the active site, blocking the
zinc from interacting with an H2O molecule, thus keeping
the enzyme in latent form until activation with the removal
of the prodomain [12]. A critical prediction of this model is
that MMPs can be activated by perturbing this cys-zinc inter-
action by chemical, physical as well as proteolytic interac-
tions. Indeed, oxidants which react with the thiol group of
cysteine, chaotropic agents such as organomercurial com-
pounds which relax the prodomain or proteinases such as
trypsin which attack the prodomain directly, can all induce
MMPs to undergo autoactivation to generate fully active
MMP enzyme [13^16]. Although the cysteine switch model
governs the latency/activation of all known MMPs, it is not
clear whether any alternative mechanism has evolved to keep
similar MMP catalytic domain latent.
Here I report the cloning of CA-MMP: a novel mouse
MMP-like gene lacking a cysteine switch in the prodomain.
Furthermore, the discovery of CA-MMP brings two novel
functional domains to the repertoire of MMP structures: a
distinct cysteine array and a novel Ig-fold domain. Character-
ization of its products con¢rms that CA-MMP is a matrix
metalloproteinase expressing strong gelatinolytic activity sen-
sitive to both synthetic as well as natural MMP inhibitors.
During the preparation of this paper, two groups have re-
ported the sequence of the human counterpart of CA-MMP.
Velasco et al. have described the sequence, tissue distribution
and chromosome localization of MMP23, while Gururajan et
al. reported the same sequence and its duplicated copy as
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MMP21/22 near the CDC2L1-2 locus at 1p36.3 [17^19]. Rec-
ognized as a novel MMP gene with distinct structure in both
reports, very little has been described about the enzymic func-
tion of human MMP21/22/23 and its key structural features
[19].
2. Materials and methods
2.1. Cell lines and reagents
General chemical reagents were either from Fisher (Pittsburg, PA,
USA) or Sigma (St. Louis, MO, USA). MDCK cells and COS 7 were
obtained and maintained as described previously [20^22]. DNA re-
striction and modi¢cation enzymes were purchased from Promega
(Madison, WI, USA). Oligonucleotide primers were synthesized at
the University of Minnesota microchemical core facility. In general,
COS cells are used for transient gene expression largely because the
pCR3.1 expression vector system is very e⁄cient in COS cells due to
the presence of SV40 T antigen. MDCK is the choice of cells for
stable expression of recombinant protein as described [21]. Anti-
FLAG M2 monoclonal antibody, its agarose beads, and FLAG pep-
tide were purchased from Kodak (Rochester, NY, USA). Human
recombinant TIMP2 was obtained from Dr. R. Fridman (Wayne
State University, MI, USA).
2.2. Cloning and analysis of CA-MMP cDNA and genomic locus
The bulk of the mouse CA-MMP gene is derived from an EST
clone AA238244 by direct sequencing. The missing 5P of CA-MMP
is recovered by cloning the genomic locus of CA-MMP from screen-
ing the genomic library of strain SVJ129 using CA-MMP cDNA as
probe. The entire coding region of CA-MMP was mapped to the
genomic locus by PCR and sequencing as shown in Fig. 1, lower
panel. A composite clone was assembled by PCR using high ¢delity
pfu enzyme and con¢rmed by sequencing. Conceptual translation of
the cDNA sequence was carried out via internet at http://www.expa-
sy.ch/. Sequence alignment was performed via Internet using program
Multalin version 5.3.3 at http://www.expasy.ch/www/tools.html using
blosum62 with Gap weight: 12; Gap length: 2.
2.3. Tissue distribution of CA-MMP by RT-PCR
Premade mouse cDNA panels (Clontech, Palo Alto, CA, USA)
were ampli¢ed with two primers: 5P TCA ATT CCT CAC TCG
GAC CC 3P, 5P CTC TAT GGC TGC CTG GAC 3P at the following
conditions: 2 min at 94‡C for denaturation, 35 cycles of 10 s at 94‡C,
30 s at 54‡C for annealing and 30 s at 72‡C for extension, followed by
10 min extension at 72‡C to generate a 420 bp fragment. To control
for the amount of cDNA used in each reaction, a parallel ampli¢ca-
tion using primers designed from the house-keeping gene GAPDH
was performed under the same experimental conditions [20].
2.4. Construction of ST3/CA-MMP-LYG and CA-MMP expression
vectors
The full-length expression vector was constructed by amplifying the
entire open reading frame of CA-MMP with primers: CA-MMP 5P
CAT CCC TTT CCC ATT CCG; CA-MMP-FLAG 3P GTC ACT
TGT CAT CGT CGT CCT TGT AGT CAT TCC TCA CTC GGA
CCC, and then inserting the PCR product into the EcoRV site of
pCR3.1uni as described. The resulting construct contains a FLAG
tag at its 3P end. The chimera ST3/CA-MMP-LYG was constructed
by high ¢delity PCR to fuse the prodomain of stromelysin-3 (ST3)1ÿ97
with the catalytic domain of CA-MMP80ÿ255 as follows [23]. Brie£y,
the prodomain of ST3 was isolated by high ¢delity PCR using two
primers: ST3 5P CGG ATG GCT CCG GCC GCC TGG CTC CGC
AGC, and ST3 3P CCT CTT CTG TCG GTT GCG GGC, and the
catalytic domain of CA-MMP using primers: CA-MMP-cat 5P CGA
CAG AAG AGG TAC ACG CTG ACA CCG GCC AGG, and CA-
MMP-cat-FLAG 3P GTC ACT TGT CAT CGT CGT CCT TGT
AGT CGC CAT AGA GTC GGT GTA AC. The resulting two
PCR fragments were combined and re-ampli¢ed with the ST3 5P
and CA-MMP-cat-FLAG 3P primers to give rise to the chimera frag-
ment. The chimera product was subsequently cloned into expression
vector pCR3.1uni at the EcoRV site. Clones with the correct orienta-
tion were identi¢ed by restriction digestion and con¢rmed by DNA
sequencing.
2.5. DNA transfection and immuno£uorescence staining
The expression construct pCR3.1uni-CA-MMP-FLAG was trans-
fected into COS cells for e⁄cient expression and the resulting prod-
ucts were analyzed by immunoprecipitation using M2 monoclonal
antibody as described [20,21]. For stable expression, the full-length
or the chimera construct was transfected into MDCK cells separately
and stable clones were selected, isolated and characterized as de-
scribed previously [20,21]. Positive clones were identi¢ed by Western
blot using anti-FLAG M2 monoclonal antibody and expanded as
described [20,21]. For immuno£uorescence, MDCK cells stably trans-
fected with control or full-length CA-MMP were ¢xed, stained with
M2 monoclonal antibody as the ¢rst antibody (1:200 dilution), FITC
conjugated rabbit anti-mouse secondary antibodies (Calbiochem, CA,
USA) and visualized under a Nikon £uorescence microscope as de-
scribed [24].
2.6. Puri¢cation and characterization of CA-MMP catalytic domain
Since the prodomain of ST3 contains a furin recognition site for
MMP activation [23], the chimera protein is expected to be processed
by furin into a fully active form, i.e. the catalytic domain. To purify
the secreted catalytic domain, a stable clone with high level of expres-
sion was expanded in 150 mm dishes to con£uence. The cultures were
then washed with phosphate-bu¡ered saline (PBS) twice, replenished
with serum free DMEM media and allowed to incubate for 48 h
before harvesting. A total of approximate 500 ml of conditioned me-
dia was collected, cleared by centrifugation, and fractionated by af-
¢nity chromatography using the M2 antibody resin (Kodak, NY,
USA) as described [21]. The proteolytic activity of puri¢ed CA-
MMP was analyzed against denatured type I collagen in the presence
or absence of MMP inhibitors BB94 or TIMP2 as described [22].
3. Results
3.1. Cloning of mouse CA-MMP cDNA and characterization
of its exon/intron structure
During a search for novel MMP related sequences in the
public EST database maintained in the National Center for
Biotechnology Information, several EST hits were analyzed
further to identify MMP-like genes from the mouse genome.
One of such ESTs, AA238244, reveals extensive homology to
human stromelysin-3 gene with identity reaching s 40% at
the catalytic domain. Subsequent sequencing of the entire
EST clone, however, predicted a putative MMP with novel
domains at the C-terminus (Fig. 1). To complete the open
reading frame, the genomic locus of this gene was isolated
from mouse genomic library (SVJ129 strain) which covers a
19 kb segment, where approximately 2.5 kb encodes the entire
exon 8 of this particular gene as determined by direct sequenc-
ing and PCR ampli¢cation (Fig. 1, lower panel). This is the
smallest MMP-like gene identi¢ed from any mammalian ge-
nome.
3.2. Structural features of CA-MMP
As shown in Fig. 1, a conceptual translation of the open
reading frame indicates that this novel MMP-like gene en-
codes: (1) a hydrophobic segment which could be the signal
peptide, (2) a potential furin recognition motif: RRRR, (3)
a conserved MMP catalytic domain, (4) a novel carboxyl ter-
minus and (5) three potential N-glycosylation sites (N93,
N149, N233) (Fig. 1).
The putative prodomain of CA-MMP lacks a cysteine
switch, but contains a furin processing site [12,23]. Although
all MMPs discovered so far contain a well conserved
PRCGXPD motif for latency, CA-MMP appears to lack
such a motif. The three cysteine residues at the N-terminus
do not appear to be available for latency because they are
either upstream or part of a hydrophobic region (bold letters
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in Fig. 1, upper panel). Surprisingly, this gene contains a
conserved furin recognition motif RRRR, which could serve
as a signal for zymogen activation, as demonstrated for
MMP11 and MMP14 [23,25,26], suggesting that the removal
of the prodomain process may be required for CA-MMP ac-
tivation.
The CA-MMP catalytic domain contains two novel inserts.
Alignment of the catalytic domain with those of a few selected
MMPs indicates strong homology surrounding the zinc bind-
ing catalytic site : HEXGHXXGXXH with the conserved M
turn as well as the Asp residue for salt bridge formation with
the N-terminus of the mature enzyme (Fig. 2A) [27]. Interest-
Fig. 1. Primary structure of mouse CA-MMP. Upper panel: Nucleotide and amino acid sequences of mouse CA-MMP. The numbering on the
right is for the amino acid sequence. The hydrophobic segment at the N-terminus is presented in bold. The putative furin recognition motif
RRRR is boxed. The zinc catalytic site is underlined with the three His and one Glu residues bolded, followed by the M turn (bold) and puta-
tive salt bridge Asp (bold). The six Cys residues which form a cysteine array are italicized, bolded and underlined. The vertical bars indicate
the positions of seven introns. Lower panel: Exon/intron and domain structure of mouse CA-MMP: The motifs and domains mentioned above
are presented schematically. RRRR and the downward arrow indicate the potential furin processing signal. The relationship between the
cDNA structure (upper line) and the genomic locus (lower line) is illustrated with connecting lines specifying the position of each exon (boxes
1^8). H, hydrophobic segment; P, prodomain; CAT, catalytic domain; CA, cysteine array; Ig, immunoglobulin C2 type fold.
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ingly, two novel inserts are present in the catalytic domain.
The ¢rst, C153LVSAVHHC161, appears to be able to form a
loop via a potential disul¢de bond whereas the other,
T193RYSWKKGV201, is positively charged (Fig. 2A).
The cysteine array motif is encoded by an anciently shu¥ed
exon. The sequence downstream of the catalytic domain does
not have any speci¢c feature other than a distinct Cys pattern
of Cys-X6-Cys-X8-Cys-X10-Cys-X3-Cys-X2-Cys (Fig. 2B).
Analysis of CA-MMP genomic structure reveals that this mo-
tif is encoded by a single exon: exon 6, suggesting an evolu-
tionary conserved domain (Fig. 1). Indeed, when this sequence
was blasted alone against sequence deposited at NCBI, the
Cys pattern matches perfectly with more than 11 entries de-
rived from the C. elegans genome project with unknown func-
tion (Fig. 2B). The same basic pattern repeats four times in
one particular sequence, U97407 (Fig. 2B). In light of this
¢nding, this MMP-like gene is named CA-MMP for cysteine
array matrix metalloproteinase.
The carboxyl end of CA-MMP contains a novel domain
with an Ig-like C2 type fold. Downstream of the cysteine
Fig. 2. Domain structure of CA-MMP. A: Comparison of domain structures between CA-MMP and MT1-MMP: The catalytic domain and
the RxK/RR signal are aligned between CA-MMP and MT1-MMP. H, hydrophobic; P, prodomain; CA, cysteine array; Ig, immunoglobulin
C2 type fold; c, cysteine switch; CAT, catalytic domain; Pexin, hemopexin-like domain; S/TM/C, stem/transmembrane/cytosolic domains.
B: Alignment of MMP catalytic domains. The catalytic domains from the following representative MMPs: mouse MMP8 (mMMP8) and
CA-MMP, frog collagenase 4 (XCOL4), human MT1-MMP (MT1), MMP12, Enamelysin and MMP11 are aligned to illustrate the degree of
homology between CA-MMP and the selected MMPs. Homologous positions to the CA-MMP sequence are marked bold. Identical residues
are marked by *, while the conserved ones by dots underneath. The two unique inserts for CA-MMP are boxed. C, cysteine array. The cysteine
rich segment of CA-MMP is aligned with protein sequences deposited in the NCBI database to identify the cysteine array in every six, eight,
ten, three and two residues. U41274, Z66520, U97407, U80452, Z71261, Z73896, P34269, U13072, U22380, Z79639 and U58755 are accession
numbers for putative genes from the C. elegans genome. The consensus is depicted at the bottom with bold letters. D, type C2 Ig-fold. The se-
quence downstream of the cysteine array has two segments of homology with those of CD80, DCC, IL1R and CD48, similar to the type C2
Ig-fold. DCC, deleted in colon cancer; IL1R, interleukin 1 receptor.
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array, there are 101 residues with a potential disul¢de bridge
(Cys322-Cys371). Within this bridging pair of cysteines, there is
a recognizable Ig-like C2 type fold similar to those in CD80,
DCC, IL1R, and CD48 (Fig. 2C) [28^31]. Thus, this motif
along with the cysteine array de¢nes a novel carboxyl termi-
nus for CA-MMP.
3.3. Expression pro¢le of CA-MMP in mouse embryo and
adult tissues
To begin to probe the physiological function of CA-MMP,
its expression pro¢le was determined in mouse embryo and
adult tissues by RT-PCR as described [20]. As shown in Fig.
3, heart, spleen and lung are the main organs/tissues express-
ing CA-MMP at relatively high levels, while tissues such as
brain, liver, skeletal muscle, kidney and testis are basically
negative. On the other hand, 7 days old mouse embryo ex-
presses CA-MMP at the highest level when compared to day
11, 15 and 17 embryos. It appears that CA-MMP expression
begins to increase on day 17 after its level drops from day
11 to 15 (Fig. 3, lanes 9^12). The onset of CA-MMP expres-
sion has not been determined due to the lack of embryos prior
to day 7.
3.4. Expression of full-length CA-MMP
Based on sequence analysis, there is a hydrophobic segment
at the N-terminus of CA-MMP which could be consistent
with either a signal peptide or type II transmembrane domain.
To begin to distinguish this possibility and explore the bio-
chemical function of CA-MMP, a full-length CA-MMP ex-
pression vector, pCR3.1uni-CA-MMP-FLAG, was con-
structed to contain a FLAG tag at its carboxyl terminus
(Fig. 4A). In a transient transfection assay into COS cells,
both the supernatants and cell lysates were analyzed to detect
any CA-MMP product using the anti-FLAG M2 antibody as
Fig. 2 (continued).
Fig. 3. Expression of CA-MMP in mouse embryo and adult tissues.
Reverse transcribed cDNA (0.5 ng aliquot each) from a multiple tis-
sue panel (Clontech, CA, USA) including heart, brain, spleen, lung,
liver, skeleton muscle, kidney testis (lanes 1^8) were ampli¢ed to
give rise to the 420 bp fragment of MT5-MMP. Similar cDNA
preparations from whole embryos aged day 7, 11, 15, 17 (E7 to 17
in lanes 9^12) were analyzed as the adult tissues. To control for the
amount of cDNA in each reaction, a parallel PCR reaction with
GAPDH speci¢c primers was carried out as suggested by the suppli-
er.
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described [21]. As shown in Fig. 4B, a main CA-MMP prod-
uct at 50 kDa was detected only in cell lysates, while the
supernatant was negative as shown in Fig. 4B (lanes 2, 4).
To con¢rm its cellular localization, stable clones were gener-
ated by transfecting CA-MMP expression vector into MDCK
cells and immunostained with M2 monoclonal antibody
against the FLAG tag. As shown in Fig. 4C, intense signals
were detected intracellularly in CA-MMP, but not the control
transfected cells. Thus, CA-MMP appears to be mainly a cell-
associated product, not readily secreted extracellularly.
3.5. Expression and characterization of CA-MMP active
proteinase
To circumvent the di⁄culty associated with puri¢cation of
a cell-associated protein, a chimera strategy was employed to
fuse the signal peptide and prodomain including the RXKR
motif of stromelysin-3 with the catalytic domain of CA-MMP.
As illustrated in Fig. 5A, this chimera construct is capable of
directing the synthesis of a fusion protein in the ER, which
will undergo furin mediated zymogen activation as reported
[23]. In addition, a FLAG tag was engineered to the C-termi-
nus to facilitate identi¢cation and puri¢cation as described
[21]. Indeed, when a stable cell line was generated by trans-
fecting the chimera construct into MDCK cells, a 32 kDa
protein product can be detected from its supernatant in large
quantity by Western blotting using M2 antibody (data not
shown). Conditioned media from this stable cell line were
subsequently collected and chromatographed on an M2 a⁄n-
ity column (0.5U2 cm). As shown in Fig. 5B, a protein species
around 32 kDa in the supernatant (lane 2) was absorbed to
the column and could be eluted with FLAG peptide at a 1:1
molar ratio (lane 4). A expected, there is a concomitant de-
crease in intensity for the protein species around 32 kDa in
the £ow-through fraction (Fig. 5B, lane 3). The puri¢ed
CA-MMP can be detected by both M2 antibody or anti-
CA-MMP speci¢c antibody on Western blots (Fig. 5B, lane
5, and data not shown). Since almost all MMPs can be as-
sayed for activity by zymography, the same preparation of
puri¢ed CA-MMP was analyzed by gelatin zymography. As
shown in lane 6 of Fig. 5B, a single gelatinolytic species was
observed in a molecular weight consistent with the puri¢ed
material. Thus, it is concluded that the CA-MMP catalytic
domain can be expressed and puri¢ed in an active form em-
ploying this chimera strategy.
CA-MMP catalytic domain expresses gelatinolytic activity
sensitive to MMP inhibitors. Since zymography is a technique
capable of detecting both latent as well as active MMPs, it is
not clear whether the puri¢ed CA-MMP is fully active as
predicted by the designing strategy. To this end, the proteo-
lytic potential of the puri¢ed CA-MMP is characterized
against denatured type I collagen (gelatin) in a solution assay.
As shown in Fig. 5C, CA-MMP cleaves gelatin e⁄ciently
(lane 2). Consistent with its homology to MMPs, the gelati-
nolytic activity of CA-MMP is inhibited by MMP inhibitors
both synthetic (BB94) or natural (TIMP2) (Fig. 5C, lanes 3
and 4). Although the cleaved sites on gelatin have not been
identi¢ed, CA-MMP appears to cleave it in a novel pattern
di¡erent from other MMPs such as gelatinase A or B, perhaps
re£ecting a unique catalytic pocket.
4. Discussion
CA-MMP is apparently the mouse homologue of human
MMP21/22 recently reported by Gururajan et al. and
MMP23 by Velasco et al. [17^19]. While both papers de-
scribed the cloning, chromosomal localization as well as tissue
distribution of the human gene, its enzymic property remains
to be de¢ned. Attempts to characterize a bacterially derived
chimera protein between prodomain of MMP19 and human
MMP23 led Velasco and colleagues to conclude that human
MMP23 has weak proteolytic activity against a synthetic sub-
strate, but absolutely no activity against protein substrate
such as gelatin [19]. This conclusion is in sharp contrast to
the ¢nding of this report that CA-MMP encodes an active
proteinase capable of degrading large protein substrates in
an MMP inhibitor sensitive fashion. It is not clear whether
this discrepancy is due to a 14% divergence between human
and mouse sequences or experimental strategies for expres-
sion. Given the inherent problem of misfolding for mamma-
Fig. 4. CA-MMP is associated with cells. A: CA-MMP-FLAG ex-
pression construct. The full-length CA-MMP was fused in-frame
with a FLAG epitope at its carboxyl terminus to facilitate detection
and puri¢cation (see Section 2). F, FLAG epitope. B: CA-MMP is
associated with cells. Control (lanes 1, 3) and mouse CA-MMP
(lanes 2, 4) expression vectors were transfected into COS cells. 48 h
post-transfection, the cells were labeled with [35S]Met (100 WCi/ml,
Amersham, IL, USA) for 3 h. The supernatants (lanes 1, 2) and cell
lysates (lanes 3, 4) were immunoprecipitated with anti-FLAG M2
monoclonal antibody as described in Section 2. The arrowhead indi-
cates the main CA-MMP species while small arrow above the ar-
rowhead marks a putative dimer of CA-MMP. C: Immuno£uores-
cence of CA-MMP products. MDCK cells stably transfected with
control (left panel) or full-length CA-MMP (right panel) vectors
were stained with M2 monoclonal antibody and then FITC conju-
gated secondary antibody as described [24].
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lian proteins expressed in E. coli, characterization of the hu-
man enzyme produced in a mammalian system will help to
clarify the di¡erences.
The physiological function of CA-MMP is presently un-
known. Expression pro¢le of its human counterpart demon-
strated a close association of CA-MMP with reproductive
processes based on high levels of expression in tissues such
as ovaries, testis and prostates [19]. While the expression of
CA-MMP in mouse reproductive tissues has not been deter-
mined, it is expressed at relatively high level in heart and lung
tissues of mouse, consistent with ¢ndings in human tissue [19].
In contrast, mouse spleen expresses signi¢cant amount of CA-
MMP while human spleen is basically negative. This di¡er-
ence may re£ect the detection sensitivity of the methods used,
i.e. RT-PCR vs. Northern blotting. While its expression dur-
ing human embryonic development has not been established,
mouse embryo at day 7 expresses CA-MMP at relatively high
level when compared to those at stages day 11, 15 and 17,
suggesting that CA-MMP may play a critical role during early
embryonic development. These data suggest a diverse picture
of CA-MMP/MMP21/22/23 expression in both embryonic
stages as well as adult tissues, thus, a potentially diverse bio-
logical function as well.
CA-MMP is a cell-associated proteinase. Based on immu-
noprecipitation and immuno£uorescence studies (Fig. 4), CA-
MMP appears to be associated with cells intracellularly with
undetectable secretion. The mechanism of cellular localization
is not clear at present. While the hydrophobic region at the N-
terminus is consistent with that of a signal peptide, it is pos-
sible that it may serve as a transmembrane domain, thus an-
Fig. 5. Expression and characterization of active CA-MMP catalytic domain. A: Expression strategy for CA-MMP catalytic domain. The puta-
tive catalytic domain of CA-MMP, Y80-G255, was fused to the prodomain of ST3, M1-R97 to form a chimera ST3/CA-MMPcat as illustrated.
A FLAG tag was engineered in-frame to the C-terminus of this construct. This construct is expected to undergo intracellular activation as de-
scribed for ST3 to generate a fully processed CAM-cat at the furin site. The abbreviations are as in Fig. 4. The block vertical bar represents
the RXK/RR motif located between catalytic and prodomains of CA-MMP and ST3. ST3, stromelysin-3/MMP11. B: Puri¢cation and charac-
terization of CA-MMPcat. MDCK cell lines stably expressing ST3/CA-MMPcat were generated by transfection, followed by selection in the
presence of G418 as described. Collected serum free media (lane 2) was cleared, passed through a 1 ml M2 agarose column (lane 3). Bound
materials were eluted with free FLAG peptide competitively and analyzed by staining (lane 4, 500 ng/lane), immunoblotting (lane 5, 25 ng/lane)
and zymography (lane 6, 25 ng). C: Proteolytic activity of CA-MMPcat. Denatured type I collagen (5 Wg in a 20 Wl reaction) was incubated
alone (lane 1) or with puri¢ed CA-MMPcat (lanes 2^4, 20 ng/lane) at 37‡C for 6 h in 50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, in the
absence (lanes 1, 2) or presence of metalloproteinase inhibitors BB94 (lane 4, 5 WM) or TIMP2 (lane 3, 50 ng). The reaction mixtures were ana-
lyzed by SDS-PAGE as described [22].
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choring CA-MMP as a type II transmembrane proteinase.
Alternatively, the novel Ig-fold and cysteine array domains
may render CA-MMP membrane- or cell-associated. Further
studies are in progress to distinguish these possibilities.
The discovery of CA-MMP demonstrates a divergent and
alternative pathway for the evolution of novel members in the
MMP superfamily with the following implications. First of
all, the lack of a classic cysteine switch and the conserved
hemopexin-like domain suggest that CA-MMP branched out
of the main MMP tree early in evolution. Indeed, a similar
MMP-like gene without a cysteine switch and a hemopexin-
like domain has been identi¢ed in this laboratory from the C.
elegans genome (unpublished data). Should CA-MMP or its
relatives evolve in parallel to the main MMP branch, it will be
interesting to see whether this alternative pathway has been as
successful as the classic MMPs with more than 20 members
[4]. The recent explosion of new MMP discoveries could be
accredited in part to degenerate RT-PCR using primers
against the conserved PRCGXPD and HEXGH motifs
[10,32^35]. This strategy will apparently fail to identify CA-
MMP-like molecule for the absence of a PRCGXPD motif.
Thus, new strategies have to be devised to uncover new CA-
MMP family members. With the rapid progress of the genome
projects on human, mouse as well as other species, a de¢nitive
answer will emerge in the near future. Secondly, proprotein
convertase mediated MMP activation/processing may be a
mechanism of activation evolved as early as MMP catalysis.
Out of all motifs and domains found in the classic MMPs,
CA-MMP possesses only the catalytic domain and the RXK/
RR activation/processing motif. Recognized originally in
MMP11 as the signal for zymogen activation [23], a similar
RXK/RR motif is present in MMP14^17 (MT1,2,3,4-MMPs)
and the newly identi¢ed MMP24/MT5-MMP [5,10,20,33^35].
Since the MT-MMPs are known to activate other MMPs
without the RXK/RR motifs such as MMP2 and MMP13
[10,36], the proprotein convertase mediated zymogen activa-
tion pathway is becoming the dominant mechanism governing
MMP activities leading to ECM breakdown. The presence of
an RXK/RR motif in a gene such as CA-MMP which
branched out early in evolution suggests that the proprotein
convertase pathway might have been the method of choice for
zymogen activation, even before the cysteine switch latency
was evolved. The validity of this argument awaits the identi-
¢cation of more CA-MMP-like genes, which have RXK/RR
motifs, but without the cysteine switch. Thirdly, the cysteine
array and Ig-like C2 fold domain located at the carboxyl
terminus of CA-MMP join the repertoire of MMP substruc-
tures such as hemopexin-like domain. In an analogy to the
classic MMPs, these two novel domains may specify substrate
speci¢city and inhibitor bindings for CA-MMP. Alternatively,
these two domains may determine cellular localization as the
full-length protein is cell-associated (Fig. 4). E¡orts are under-
way to uncover the contribution of these two motifs to CA-
MMP function biochemically. Finally, CA-MMP may possess
a novel mechanism of latency. The presence of an RXK/RR
motif suggests that the prodomain of CA-MMP will be
cleaved o¡ by furin or related enzymes in the trans-Golgi
network. Given the fact that all MMPs discovered so far
are encoded as zymogens, it is likely that CA-MMP is synthe-
sized as a zymogen and processed into active form by furin or
furin-like enzymes [23,37]. Since CA-MMP has no cysteine
residue in the prodomain, it may have a novel mechanism
of latency. Elucidation of its latency mechanism will broaden
our understanding of structural/functional relationships for
the MMP gene family. Taken together, CA-MMP along
with its human counterpart MMP21/22/23 helps de¢ne a
new subfamily of MMPs with distinct structures and potential
functional consequences in ECM remodeling.
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